Researchers just took a big step towards developing what might be the first 'universal cancer vaccine'.
The outcomes from early trials in humans, together with research in mice, have just been published, and they suggest that the new method might be used to trigger clients' body immune systems against any type of tumour, no matter where it is in the body.
Unlike the vaccines we're familiar with, this possible vaccine would be given to patients who currently have cancer, rather than those at danger of getting it. It basically works by shooting tiny 'darts' including pieces of RNA extracted from the client's cancer cells at the body's own body immune system, causing them to launch a full-scale attack on any tumours they find.
By just changing the RNA inside those darts, the group can, in theory, mobilise the body immune system against any type of cancer." [Such] vaccines are quick and low-cost to produce, and virtually any tumour antigen can be encoded by RNA," the team, led by scientists at Johannes Gutenberg University of Mainz in Germany, reports in Nature.
"Thus, the nanoparticulate RNA immunotherapy approach introduced here may be regarded as a universally applicable novel vaccine class for cancer immunotherapy."
Immunotherapy, which involves using the patient's own body immune system to attack cancer, isn't really in itself brand-new - researchers are already using it against different cancer types with terrific outcomes.
However previously, researchers have actually primarily done this by genetically engineering special, cancer-targeting immune cells in the lab, and after that injecting them back into a client - which is a time-consuming and costly procedure.
The difference with this technique is that the vaccine is made in the lab, and it introduces the cancer DNA into the immune cells within the body, which is a lot less intrusive. It also indicates that the vaccine can be fine-tuned to hunt a variety of cancer types.
So why isn't the body immune system naturally getting these cancer types?
"One reason is that cancer cells are similar in many ways to normal cells and the immune system avoids attacking the self," stated Dutch immunologists Jolanda de Vries and Figdor in a commentary associated with the Nature paper.
That implies that when you develop a vaccine, you need to utilize an antigen - a foreign particle that works like a 'mugshot' for the body immune system - that's not expressed in typical cells, too.
" Just fairly modest immune reactions accompany vaccines containing antigens that are likewise revealed on healthy tissue," write de Vries and Carl Figdor. "Strong immune responses can be expected just when cancer cells reveal antigens that are not usually revealed in normal adult cells."
It's this type of cancer-specific antigen that the brand-new vaccine is created to deliver to the immune system. It works by finishing the cancer RNA in an easy, fat membrane, and providing it a somewhat negative charge.
This means that when the vaccine is injected into a patient, it's drawn through electrical charge to dendritic immune cells in the spleen, lymph nodes, and bone marrow.
These dendritic cells then 'show' the cancer RNA to the body's T cells and, to anthropomorphise the scenario, practically inform them, "Hey, this is the man we seek, go get him." The objective is that the T cells will then head out and mass murder all the cancer cells in the body.
And this is what early research by the German group has actually shown in mice. When injected with the vaccine, the body immune system was able to battle "aggressively growing" tumours, the research study found.
Naturally, many outcomes in mice don't equate to human beings, so we can't get too thrilled right now.
The team has actually likewise now trialled a variation of the vaccine in 3 patients with melanoma. The point of the trial was only to test whether the vaccine was safe to utilize in people, not whether it was effective, and so far, the outcomes are appealing. The side results were limited to flu-like signs, which is better than many chemotherapy treatments.
The group is now waiting 12 months for follow-up arise from this safety trial, and if all goes well, will start a larger medical trial after that to see if the vaccine actually works.
"By combining laboratory-based studies with results from an early-phase clinical trial, this research shows that a new type of treatment vaccine could be used to treat patients with melanoma by boosting the effects of their immune systems," Aine McCarthy, the senior science info officer at Cancer Research UK, told The Telegraph.
" Because the vaccine was just checked in 3 patients, larger medical trials are required to confirm it works and is safe, while more research will identify if it could be used to treat other kinds of cancer."
Although it's still extremely early days, we have another reason to feel confident about the future of cancer treatment. And that's constantly an advantage.
Thanks for taking the time to read this article. If you found this information helpful, please share it with your friends and family. Your support in our endeavor of sharing free information would be much appreciated.
You have permission to republish this article under a Creative Commons license with attribution to Deprogram Yourself